Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Can Fite Biopharma Ltd

CANF ✓ COMPLIANTFree checks used up today ☆ Track — members

NYSE MKT · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: N/A

Last Close

$1.62

▼ -2.41%

Market Cap $5.14M · Vol 4.03K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$5.14M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

22.95

Momentum

Beta

1.20

vs Market

52W High

$12.27

86.80% below

52W Low

$1.61

0.62% above

Volume

4.03K

Avg 3.09K

P/B

0.01

Price-to-book

ROE

N/A

Return on equity

Free Float

100.00%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Can Fite Biopharma Ltd (CANF) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CANF pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-8.99%

-26.36%

-50.61%

-49.22%

YTD

-59.50%

-81.14%

-96.01%

-99.47%

Financials & Valuation

TTM · Annual

Total Revenue	N/A
Net Income	N/A
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-2,456.79%
Net Profit Margin	-2,426.67%
ROE	N/A
ROA · ROIC	N/A · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	0.05
P/B	0.01
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	6.07M

Technical Indicators

50-Day SMA	$2.26
200-Day SMA	$3.21
RSI (14)	22.95
Beta	1.20
52-Week High	$12.27
52-Week Low	$1.61

Volume Today	4.03K
Avg Daily Volume (30D)	3.09K
Relative Volume	1.30x
Volatility (10D)	49.29
Volatility (30D)	41.44
Free Float	100.00%

Analyst Consensus

N/A

Current Price $1.62

Mean Target $50.00

52W Low$1.61 52W High$12.27

Current

Target

$1.61 $12.27

Current Analyst target

+2,986.42% upside potential · 0 analysts

Identifiers

ExchangeNYSE MKT

FIGIBBG003CMFFC8

ISINUS13471N4097

CountryIsrael

Sub-IndustryBiopharmaceuticals

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals, Inc. +13.33% CSL.AX CSL Limited +1.64% UCB.BR Ucb SA +0.50% 207940.KS SAMSUNG BIOLOGICS CO.,LTD. +8.86% BIIB Biogen Inc. +1.59%

Company Profile

Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.